Biogen Shares Rise on Q4 Earnings Beat Despite Lower Revenue Outlook

Shares of Biogen Inc (BIIB) rose 8.53% to $201.18 at close on Friday following the release of fourth-quarter and full-year 2025 financial results. The stock traded within a 52-week range of $110.04 to $202.41 (intraday high), showing a strong recovery from mid-2025 lows as the company executes its “Fit for Growth” restructuring and advances new product launches.

Company Description: Biogen is a global biotechnology company specialized in the discovery and development of therapies for neurological and neurodegenerative diseases. Its core commercial portfolio includes treatments for multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer’s disease, alongside a growing biosimilars business. The company operates primarily in North American, European, and Asian markets, serving healthcare providers and patients through direct sales and strategic collaborations.

Current Stock Price: $201.18 (close, Feb 6, 2026)

Market Capitalization: Approximately $29.5 billion

Valuation: Biogen’s forward P/E ratio is currently in the low-to-mid teens based on 2026 earnings estimates. This multiple reflects market caution regarding the mid-single digit revenue decline projected for 2026, balanced against significant cost-saving initiatives expected to support EPS stability or modest growth.

Q4 Results: Earnings Beat Estimates Amid MS Decline

Biogen reported fourth-quarter 2025 revenue of $2.28 billion, exceeding analyst forecasts of $2.21 billion but declining 7% year-over-year. The decline was driven primarily by continued generic erosion in the multiple sclerosis (MS) franchise and a 15% drop in SPINRAZA revenue due to shipment timing outside the U.S.

Non-GAAP Diluted EPS: $1.99 (compared to $3.44 in Q4 2024), beating consensus of approximately $1.61–$1.72.
GAAP Diluted EPS: $(0.33) net loss, impacted by $222 million in milestone and upfront payments for research and development.
Leqembi Performance: Global in-market sales reached $134 million, with strong sequential and year-over-year growth.

For the full year 2025, total revenue reached $9.9 billion, up 2% over 2024. Non-GAAP diluted EPS for the year was $15.28, surpassing the upper end of previous guidance.

2026 Outlook and Macro Pressures

Biogen issued 2026 financial guidance projecting total revenue to decline by a mid-single digit percentage compared to 2025. The company expects non-GAAP diluted EPS to be between $15.25 and $16.25.

The company highlighted sector-wide challenges, including increasing competition from generic versions and biosimilars of MS products, particularly TECFIDERA in Europe. Geopolitical risks remain centered on global supply chain stability and potential regulatory shifts in international markets, though no specific material tariff impacts were quantified in the year-end report. Biogen’s “Fit for Growth” program is on track to deliver $1 billion in gross savings by the end of 2025 to offset these pressures.

Biogen Inc (BIIB) SWOT Analysis

Strengths

Market Leadership: Dominant position in anti-amyloid Alzheimer’s therapy with Leqembi (over 60% market share).
Cost Discipline: Fit for Growth program yielding significant net savings; free cash flow of $2.1 billion in 2025.
Product Diversification: Rapid growth in new launches (Skyclarys, Zurzuvae, others) contributing meaningfully to revenue.

Weaknesses

Revenue Concentration: High reliance on the MS franchise, which continues to face double-digit generic erosion.
Negative GAAP Earnings: Significant pre-tax charges for litigation and R&D milestones led to a Q4 GAAP loss.
Spinraza Volatility: 15% Q4 revenue decline due to shipment timing outside the U.S.

Opportunities

Pipeline Milestones: Multiple potentially registrational studies expected to read out over the next four years.
Global Expansion: Launch of subcutaneous Leqembi (IQLIK) and further approvals for Zurzuvae provide new growth runways.
Biosimilars Growth: Stable contribution from the biosimilars segment to offset branded MS declines.

Threats

Generic Competition: Continued price and volume pressure from lower-priced MS alternatives in key jurisdictions.
Regulatory Delays: Risk associated with resubmissions, such as the high-dose Spinraza PDUFA date in April 2026.
Macro Environment: Potential impacts from the Inflation Reduction Act and global pricing reforms.